Lilly Gets Protein Optimization System In Applied Molecular Evolution Deal
Executive Summary
Lilly's acquisition of Applied Molecular Evolution will give the company access to technology for optimizing proteins and genes for specific therapeutic targets
You may also be interested in...
BIO Notebook, Day 3: Lilly Expands R&D Site, Sigilon Raises Cash And CytomX Talks Deal Strategy
Day three at the BIO International Convention included an off-site visit to Lilly's newly expanded R&D site as well as conversations with Sigilon about the $23m Series A venture funding round it announced that morning and with CytomX about its dealmaking strategy.
Merger Outlook For 2004: Pfizer Fortunes Key To More M&A, Analysts Say
A demonstration by Pfizer of renewed vigor following the acquisition of Pharmacia could kick off another round of merger & acquisition activity in 2004, securities analysts predict
Merger Outlook For 2004: Pfizer Fortunes Key To More M&A, Analysts Say
A demonstration by Pfizer of renewed vigor following the acquisition of Pharmacia could kick off another round of merger & acquisition activity in 2004, securities analysts predict